Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a ...
New regional identity unites a more than $100 billion bioscience ecosystem and positions Indiana among the world's leading innovation hubs. BIO Internat...
Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals O...
As the biopharmaceutical industry enters a new phase of growth, manufacturers are under increasing pressure to deliver greater capacity, accelerate...
During BIO 2026, taking place June 22–25 at the San Diego Convention Center, BioPharma Boardroom spoke with Francis...
As biopharmaceutical innovation continues to evolve, analytical science is playing a more strategic role in accelerating development and supporting regulat...
The biologics development landscape is becoming increasingly complex, requiring partners that offer more than manufacturing capacity alone. As biotech comp...
As demand grows for increasingly sophisticated DNA and RNA-based therapies, the industry's focus is expanding beyond scientific discovery to the infrastruc...
Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalati...
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therape...
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome&r...
© 2026 Biopharma Boardroom. All Rights Reserved.
